{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T13:57:55Z","timestamp":1792936675170,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.jaad.2011.05.038","type":"journal-article","created":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T08:46:47Z","timestamp":1311929207000},"page":"e179-e185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-\u03b1 inhibitors: The Mayo Clinic experience, 1998 to 2010"],"prefix":"10.1016","volume":"67","author":[{"given":"Eugenia","family":"Shmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Wetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara B.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Pittelkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2011.05.038_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.0906-6705.2004.00205.x","article-title":"Biology of tumor necrosis factor-\u03b1: implications for psoriasis","volume":"13","author":"Schottelius","year":"2004","journal-title":"Exp Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2011.05.038_bib2","doi-asserted-by":"crossref","first-page":"III2","DOI":"10.1136\/ard.60.90003.iii2","article-title":"Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)","volume":"60","author":"Furst","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2011.05.038_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.sder.2005.01.007","article-title":"Overview of biologic agents in medicine and dermatology","volume":"24","author":"Sobell","year":"2005","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2011.05.038_bib4","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2004.020719","article-title":"TNF\u03b1 therapy in psoriatic arthritis and psoriasis","volume":"63","author":"Mease","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2011.05.038_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2009.08.046","article-title":"Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes","volume":"124","author":"Zaba","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2011.05.038_bib6","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.4049\/jimmunol.175.8.5024","article-title":"Paradoxical anti-inflammatory actions of TNF-\u03b1: inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells","volume":"175","author":"Zakharova","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2011.05.038_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00063030-200519010-00006","article-title":"TNF\u03b1 inhibitors in the treatment of psoriasis and psoriatic arthritis","volume":"19","author":"Tobin","year":"2005","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaad.2011.05.038_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2011.05.038_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2011.05.038_bib10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2011.05.038_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF-[alpha] inhibitors in patients with rheumatologic conditions","volume":"143","author":"de Gannes","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2011.05.038_bib12","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00002281-200307000-00003","article-title":"Tumor necrosis factor biology in experimental and clinical arthritis","volume":"15","author":"Sfikakis","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2011.05.038_bib13","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1084\/jem.174.6.1461","article-title":"The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1","volume":"174","author":"Berg","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2011.05.038_bib14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S","article-title":"Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation","volume":"194","author":"Flier","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.jaad.2011.05.038_bib15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/ard.2007.082842","article-title":"Psoriasiform lesions induced by tumor necrosis factor antagonists: a skin-deep medical conundrum","volume":"67","author":"Carter","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2011.05.038_bib16","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.4049\/jimmunol.1000313","article-title":"IL-1RL2 and its ligands contribute to the cytokine network in psoriasis","volume":"185","author":"Blumberg","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2011.05.038_bib17","doi-asserted-by":"crossref","unstructured":"Guilloteau K, Paris I, Pedretti N, Boniface K, Juchaux F, Huguier V, et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1\u03b1, and TNF-\u03b1 recapitulates some features of psoriasis. J Immunol doi: 10.4049\/jimmunol.0902464. Published online March 24, 2010.","DOI":"10.4049\/jimmunol.0902464"},{"key":"10.1016\/j.jaad.2011.05.038_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7326\/0003-4819-153-1-201007060-00030","article-title":"Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations","volume":"153","author":"Viguier","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2011.05.038_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0923-1811(98)00074-7","article-title":"Endogenous neutralizing anti-IL-1 alpha autoantibodies in inflammatory skin diseases: possible natural inhibitor for over expressed epidermal IL-1","volume":"20","author":"Mizutani","year":"1998","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2011.05.038_bib20","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2011.05.038_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.RHU.0000062513.64012.1d","article-title":"Differentiating the new rheumatoid arthritis biologic therapies","volume":"9","author":"Weaver","year":"2003","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaad.2011.05.038_bib22","series-title":"Enbrel (etanercept) [package insert]","year":"2002"},{"key":"10.1016\/j.jaad.2011.05.038_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0738-081X(98)00005-4","article-title":"Drugs in exacerbation and provocation of psoriasis","volume":"16","author":"Tsankov","year":"1998","journal-title":"Clin Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962211006207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962211006207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:24:55Z","timestamp":1759271095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962211006207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0190962211006207"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2011.05.038","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-\u03b1 inhibitors: The Mayo Clinic experience, 1998 to 2010","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2011.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}